Switch acceptance and persistence of adalimumab biosimilars in IBD patients: a prospective observational study

Background: Prospective data about the acceptance and outcomes of switching from the adalimumab (ADA) reference product (RP) to multiple ADA biosimilars in inflammatory bowel disease (IBD) patients are lacking. Objectives: To evaluate the acceptance rate of switching from the ADA RP to ADA biosimila...

Full description

Saved in:
Bibliographic Details
Main Authors: Gabrielle D’Abbundo, Maria Nachury, Alice Wartski, Aurélie Blondeaux, Sofia Hambli, Romain Gérard, Pierre Desreumaux, Nicolas Duveau, Pauline Wils
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848251332025
Tags: Add Tag
No Tags, Be the first to tag this record!